MetaCap

Artiva Biotherapeutics (ARTV) vs Palisade Bio (PALI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Artiva Biotherapeutics (ARTV) has outperformed Palisade Bio (PALI) over the past year, gaining 20.8% versus a loss of 60.6%. Artiva Biotherapeutics is the larger company by market cap ($186.9 million vs $150.7 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ARTV+20.77%PALI-60.57%
+347%+134%-80%
Nov 21, 20251 yearNov 20, 2026
ARTV-68.50%PALI-80.60%
+38%-28%-94%
Jul 15, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ARTV versus PALI key metrics
MetricARTVPALI
Share price$3.78$0.8399
Market cap$186.85M$150.74M
1-day change-1.31%-9.24%
YTD return-11.89%-64.26%
1-year return+20.77%-60.57%
5-year return—-99.95%
P/E ratio (TTM)—0.91
EPS (TTM)$-2.85$0.92
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$0
Revenue growth (YoY)-100.00%—
Net income (latest FY)$-83.86M$-16.78M
52-week high$14.53$2.86
52-week low$2.96$0.8381
Distance from 52-week high-73.98%-70.63%
Analyst consensusbuystrong_buy
Avg. price target upside+448.94%+935.84%
Average volume792.26K3.19M
Shares outstanding49.43M179.28M
Employees13414
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ARTV has outperformed PALI by 81.3 percentage points over the past year.

About Artiva Biotherapeutics

ARTV stock →

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 134 employees

About Palisade Bio

PALI stock →

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees

ARTV vs PALI FAQ

Which is bigger, Artiva Biotherapeutics or Palisade Bio?

Artiva Biotherapeutics (ARTV) is larger, with a market capitalization of $186.85M compared with $150.74M for Palisade Bio (PALI).

Which stock has performed better over the past year, ARTV or PALI?

ARTV returned +20.77% over the past 12 months, compared with -60.57% for PALI (price return, excluding dividends). Past performance does not predict future results.

Are Artiva Biotherapeutics and Palisade Bio in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons